BMAP-27 acetate is a cationic amphipathic α-helical antimicrobial peptide with anticancer activity. BMAP-27 acetate disrupts the integrity and permeability of cell membranes, leading to the leakage of intracellular DNA, proteins and alkaline phosphatase. BMAP-27 acetate increases intracellular ROS levels and reduces plasma endotoxin and TNF-α concentrations. BMAP-27 acetate can be used in studies related to Salmonella infection, breast cancer, lung cancer and obstructive jaundice [1] [2] [3].
In Vivo, BMAP-27 (1 mg/kg; i.p.; single administration) TFA significantly reduces plasma levels of endotoxin, TNF-α and IL-6, decreases bacterial translocation, and reduces the mortality rate to 15% in mice with endotoxemia induced by bile duct ligation and LPS [3].
In Vitro, BMAP-27 (2-4 μM) TFA potently inhibits the growth of S. aureus and E. coli with MIC values of 2-4 μM[2]. BMAP-27 (2-5 μM; 20-60 min) TFA rapidly kills S. aureus and E. coli, achieving near-complete bacterial death within 20 min at its MIC of 2 μM[2]. BMAP-27 TFA efficiently depolarises the cytoplasmic membranes of S. aureus and E. coli at concentrations lower than its MIC of 2-4 μM[2]. BMAP-27 (2 days) TFA exhibits strong dose-dependent cytotoxicity against human MDA-361 and A549 cancer cells, with IC50 values lower than its haemolytic activity IC50[2]. BMAP-27 (1 h) TFA exhibits moderate dose-dependent haemolytic activity against human red blood cells[2]. BMAP-27 (5-32 μM; 2-5 min) TFA potently disrupts anionic POPC/POPG (2:1) membranes, shows moderate disruption of zwitterionic POPC/cholesterol (4:1) membranes at high concentrations, and exhibits Phosphatidylserine (PS) -dependent membrane disruption that correlates with its anticancer activity[2].
References:
[1]. Xia R, et al. Insight into the inhibitory activity and mechanism of bovine cathelicidin BMAP 27 against Salmonella Typhimurium. Microbial pathogenesis. 2024 Feb;187:106540.
[2]. Yang S, et al. Structural analysis and mode of action of BMAP-27, a cathelicidin-derived antimicrobial peptide. Peptides. 2019 Aug;118:170106.
[3]. Ghiselli R, et al. Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide. Peptides. 2006 Nov;27(11):2592-9.
In Vivo, BMAP-27 (1 mg/kg; i.p.; single administration) TFA significantly reduces plasma levels of endotoxin, TNF-α and IL-6, decreases bacterial translocation, and reduces the mortality rate to 15% in mice with endotoxemia induced by bile duct ligation and LPS [3].
In Vitro, BMAP-27 (2-4 μM) TFA potently inhibits the growth of S. aureus and E. coli with MIC values of 2-4 μM[2]. BMAP-27 (2-5 μM; 20-60 min) TFA rapidly kills S. aureus and E. coli, achieving near-complete bacterial death within 20 min at its MIC of 2 μM[2]. BMAP-27 TFA efficiently depolarises the cytoplasmic membranes of S. aureus and E. coli at concentrations lower than its MIC of 2-4 μM[2]. BMAP-27 (2 days) TFA exhibits strong dose-dependent cytotoxicity against human MDA-361 and A549 cancer cells, with IC50 values lower than its haemolytic activity IC50[2]. BMAP-27 (1 h) TFA exhibits moderate dose-dependent haemolytic activity against human red blood cells[2]. BMAP-27 (5-32 μM; 2-5 min) TFA potently disrupts anionic POPC/POPG (2:1) membranes, shows moderate disruption of zwitterionic POPC/cholesterol (4:1) membranes at high concentrations, and exhibits Phosphatidylserine (PS) -dependent membrane disruption that correlates with its anticancer activity[2].
References:
[1]. Xia R, et al. Insight into the inhibitory activity and mechanism of bovine cathelicidin BMAP 27 against Salmonella Typhimurium. Microbial pathogenesis. 2024 Feb;187:106540.
[2]. Yang S, et al. Structural analysis and mode of action of BMAP-27, a cathelicidin-derived antimicrobial peptide. Peptides. 2019 Aug;118:170106.
[3]. Ghiselli R, et al. Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide. Peptides. 2006 Nov;27(11):2592-9.